AXIN2 and cancer: Whilst ubiquitin-mediated proteolysis maintains β-catenin levels low in normal cells68, cancer cells often harbour mutations that inactivate the destruction complex consisting of GSK3β, APC and AXIN2, leading to β-catenin stabilisation.